Skip to main content

INDIA- The Growth Engine

The economy minister, Shaktikanta Das, has given his prediction of India's GDP growth for the coming 2017 - 2018 fiscal year. He says that it will be upwards of 7% and there's not any reason to doubt him.

The Gross Domestic Product (GDP) in India expanded 1.80 percent in the third quarter of 2016 over the previous quarter. GDP Growth Rate in India averaged 1.67 percent from 1996 until 2016, reaching an all-time high of 5.80 percent in the second quarter of 2009.Here are stats related to some popular markets:



The only potential fly in the ointment any of us can see for India's economic growth is the effects of demonetization, and whatever they are they are now--it has happened, and it has gone. Macroeconomic conditions are such that the government is providing a modest boost to the economy with a smallish budget deficit. Inflation is not negligible, but it does appear under control. Much to most of the growth is domestic and not affected all that much by the global lassitude in growth.

Ongoing efforts to restructure bank balance sheets to revive lending and reduce excessive leverage at large corporations is setting the stage for a recovery in investment spending likely to drive growth higher in FY2017.Healthcare has become one of India’s largest sectors - both in terms of revenue and employment. The Indian wellness industry was estimated at close to Rs85,000 crore in the financial year 2014-15 and is expected to grow at a compounded annual growth rate (CAGR) of nearly 12% for the next five years. The industry can achieve about Rs1.5 trillion by FY20, according to a recent report by Ficci and EY.

In India, we will see a radical consolidation in the healthcare industry owing to several scenarios. Mega-corporations will have the advantage over mom-and-pop shows. I assume that apart from the government, three-four large players, some of them international giants, will dominate 80% of the market.

The sheer size of our country will attract investment in healthcare infrastructure, divided between increasing the reach and deployment of technology. High-end communication technologies, devices and platforms will form the backbone of effective range. Analytics and big data will be the direction setters for the way patients are treated, medically or otherwise.I am reasonably sure that the practices of medical professionals will be largely institutionalised owing to super-specialization. The design of current set-ups like hospitals will see a sea change. In all probability, they will become diagnostic and treatment stations, while recuperation will be shifted to homes.

The India Conference is one of the largest student-run conferences focusing on India in the USA. It is hosted by the Harvard Business School and Harvard Kennedy School by the graduate students of Harvard University.

In 2017, India Conference will be celebrating our 14th anniversary. The conference will bring together business leaders, entertainment professionals, government officials, philanthropists, and many other leaders to engage in a conversation about India’s path to global leadership. Our 2016 conference had over 1000 attendees and was a resounding success.

Learn more from experts at India conference about Union budget measures, infrastructure, arts, technology growth, rural economy, new businesses, global synergies and demonetization. Refer to the agenda here and register.

Sources:

ADB-https://www.adb.org/countries/india/economy#tabs-0-2

Forbes: http://www.forbes.com/sites/timworstall/2017/02/04/indias-gdp-growth-for-fiscal-2017-to-be-upwards-of-7-shaktikanta-das/#1f0f379e653b

News Livemint- http://www.livemint.com/Politics/H50PvO2qmDaapNgNN6KWZM/India-in-10-years-Healthcare-sector-will-see-radical-consol.html

Popular posts from this blog

Artificial Intelligence Policy and Governance in HEALTHCARE

  Artificial Intelligence has become the new frontier for digital transformation. Several  #digitalhealth  businesses of today rely on Machine Learning,  #AI  and other such technologies to make healthcare delivery more efficient and comprehensive. However, the efficient and responsible use of AI tools is an ongoing discussion and would mean culture, data management, technology shifts in the industry, and required up-grading and training professionals for better coordination. Hence, with the growing market potential and interest in AI, it is imperative to develop a thoughtthrough regulatory and legal framework on the adoption and use of AI. I have set forward a hypotheses to design a policy framework for AI technologies in my paper- "𝐀𝐫𝐭𝐢𝐟𝐢𝐜𝐢𝐚𝐥 𝐈𝐧𝐭𝐞𝐥𝐥𝐢𝐠𝐞𝐧𝐜𝐞 𝐢𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐏𝐨𝐥𝐢𝐜𝐲 – 𝐀 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞" last year https://lnkd.in/emi3XWwa cited further by "𝐓𝐡𝐞 𝐐𝐮𝐚𝐧𝐝𝐚𝐫𝐲 𝐢𝐧 𝐃𝐚𝐭𝐚 𝐏𝐫𝐨𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐑

Artificial intelligence and Technology for Dentistry

Have you heard of this company  ORCA Dental AI ? ORCA combines clinical expertise with machine learning and AI technologies to create diagnostic reports, treatment plan suggestions and smart clinical predictions. Good to learn about these innovations that benefit every stakeholder in the value chain. Recently,  VideaHealth  raised $20M to Expand AI-Based Diagnostics led by Spark Capital including existing investors Zetta Venture Partners. Among its many benefits to dentists and patients are: – A 31% increase in diagnosis rate for cavities and 26% increase in treatment plan value; – An increase in case acceptance by patients due to second opinions; – Automated workflows accelerate treatment planning and charting; Another company touting AI-powered dental care and practice management is  Overjet , which announced a $42.5 million Series B funding round in December months after it had scored $27 million in Series A funding.  Pearl  provides AI for dental images to assist in diagnosis. It l

Big Data Analytics- The Microscope and Telescope for Pharma/CRO

This article is produced in consultation with Industry experts, and KOLs in India and across the world and especially highlights how “Predictive Analytics algorithms” are poised to provide Useful Analytics to the Pharma industry.   In today’s highly competitive market, it is extremely important for contract research and manufacturers to have access to information that allows them to target the specific segments of the pharmaceutical and biotechnology industry that are looking to outsource the particular services they provide.  Understanding shifts in annual outsourcing budgets and spending can help CROs and CMOs to better position themselves for capturing business, particularly at a time when many – if not all – pharma and biotech companies are looking to cut costs and streamline operations.  As per a recent report by NiceInsights, Analytical Services, Clinical Research, and Clinical Monitoring will be the most demanded services over the next 12 to 18 months. For CROs and CMOs looki